A 10 mg BPC-157/TB-500 vial cannot be safely reconstituted for human use from an online chart alone. The label does not establish a safe dose, blend ratio, route, or volume of liquid to add. BPC-157 and TB-500 are not FDA-approved for any human indication, and self-injecting research-use-only products carries real sterility and labeling risks. 1 2
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →What does “reconstitute a 10 mg BPC-157/TB-500 blend” mean?
Reconstitution means dissolving a dry, freeze-dried material in a liquid. A vial may contain lyophilized peptide powder, which is powder with water removed to improve storage stability. Adding liquid creates a solution with a measurable concentration; it does not create clinical evidence, confirm sterility, or make a research product appropriate for injection. 1 6
Why adding liquid changes concentration, not total peptide amount
If a vial truly contains 10 mg total peptide, adding liquid spreads that same 10 mg through a larger or smaller final volume. More liquid means a lower concentration per milliliter; less liquid means a higher concentration per milliliter. This is basic arithmetic, not a dosing recommendation. It cannot account for whether the vial contains the stated ingredient, amount, or blend ratio. 1
Why a 10 mg blend may not mean 10 mg of each peptide
A label reading “BPC-157/TB-500 10 mg blend” is ambiguous unless it separately lists the amount of each component. It could mean 5 mg plus 5 mg, another ratio totaling 10 mg, or a product whose contents cannot be independently confirmed. BPC-157 is also called Body Protection Compound 157, Pentadecapeptide BPC 157, or PL 14736. TB-500 is often described as a thymosin beta-4 fragment, but it is not automatically interchangeable with full-length thymosin beta-4 studied in other settings. 3 7
Can you calculate the concentration of a 10 mg BPC-157/TB-500 vial?
Yes, you can calculate a labeled vial’s 10 mg total amount divided by its final liquid volume. But that calculation is concentration math only. It is not a patient protocol, an injection instruction, or evidence that any amount is safe for subcutaneous injection. 1
The general formula is: total labeled amount ÷ final liquid volume = concentration. For example, 10 mg divided by 2 mL equals 5 mg/mL total blend concentration. It does not reveal how much BPC-157 versus TB-500 is present unless the product label provides a verified component breakdown.
| Labeled total blend amount | Final liquid volume | Math-only total blend concentration | What the calculation cannot tell you |
|---|---|---|---|
| 10 mg | 1 mL | 10 mg/mL | Whether the vial contains 10 mg, its BPC-157:TB-500 ratio, or whether it is sterile |
| 10 mg | 2 mL | 5 mg/mL | A safe human dose, route, frequency, or treatment duration |
| 10 mg | 3 mL | 3.33 mg/mL | Whether the material is appropriate for self-injection |
| 10 mg | 4 mL | 2.5 mg/mL | Whether either peptide will help a specific injury |
Why U-100 syringe units can be misread
A U-100 insulin syringe is marked in volume units designed for U-100 insulin products. Those markings do not convert directly into a peptide dose without knowing the exact, verified concentration. A syringe marking also cannot solve the larger safety questions: ingredient identity, sterility, correct route, and clinical appropriateness. 1 6
Why do online posts mention bacteriostatic water for peptide blends?
Online discussions often mention bacteriostatic water, which is sterile water containing 0.9% benzyl alcohol as a preservative. They may also mention sterile water for injection. These product terms describe diluents, not approval for mixing a particular research peptide for self-injection. 1
You may see 2 mL and 3 mL examples online because they produce easy-to-calculate concentrations. Those conventions are not validated human protocols for BPC-157 or TB-500. A proper preparation decision depends on the actual product, the pharmacy or manufacturer’s validated instructions, intended use, compatibility, and sterile handling controls—not on a popular calculator. 1 6
Why shouldn’t patients follow online BPC-157/TB-500 reconstitution instructions?
The main issue is not whether the division is difficult. It is that research-use-only products are not patient-care products. Online instructions cannot establish product identity, purity, sterility, storage history, clinical suitability, or safe injection technique. 1 6
- Contamination can cause local infection or more serious illness after an injection. Sterile preparation requires controlled processes that a social-media post cannot verify. 1
- A mislabeled concentration or blend ratio can make syringe-based calculations wrong even when the math itself is correct. 6
- A product sold for laboratory research is not labeled or manufactured as a prescription medicine for human injection. FDA warns consumers to use care when buying medicines and to understand the source of a product. 2
- Neither BPC-157 nor TB-500 has an FDA-approved label that provides a patient dose, route, reconstitution method, or duration of use. 1
For a broader look at sourcing and clinician oversight, see our guide to where to get peptide injections safely. It explains why a prescription pathway and a state-licensed pharmacy are meaningfully different from buying injectable material from an unverified online seller.
What is the evidence for BPC-157 and TB-500 in humans?
The honest answer is that human evidence remains limited. BPC-157 has a small amount of published human information, while much of its tendon, ligament, muscle strain, angiogenesis, cell migration, and fibroblast activity discussion comes from preclinical work. There is no completed human trial establishing that a BPC-157/TB-500 blend safely improves recovery after injury. 3 4 6
BPC-157: limited human data, larger preclinical literature
Reviews describe BPC-157 as a peptide investigated in animal and laboratory models of soft-tissue healing. Those models have explored blood-vessel signaling, tissue repair, and musculoskeletal effects, but animal and cell findings do not prove a human benefit. One published 2021 report described intra-articular BPC-157 use for knee pain; it was not a large randomized trial and does not validate self-injected blends, reconstitution volumes, or doses. 3 4 5
TB-500 and thymosin beta-4 are not automatically the same evidence base
TB-500 is commonly marketed as a thymosin beta-4-related peptide. Thymosin beta-4 has biological roles related to actin sequestration and cell migration, which helps explain why it has been studied in tissue-repair research. But a study involving thymosin beta-4 biology in chronic ischemic heart failure does not establish the safety or effectiveness of TB-500 for sports injuries, nor does it validate a combined BPC-157/TB-500 injection protocol. 7
Combination use has a bigger evidence gap
The internet often calls BPC-157 plus TB-500 a “Wolverine stack,” but that is a marketing term, not a standardized medical treatment. A combination can have different risks from either ingredient alone, and there are no robust human combination trials that establish an appropriate ratio, dose, route, or duration. Read our detailed review of BPC-157 and TB-500 together for a closer look at the gap between claims and evidence. 6
Registered trials are not completed proof
ClinicalTrials.gov lists studies of BPC-157 for recovery-related questions, including a planned phase 1 study after rotator cuff repair and a recruiting phase 2 study for acute hamstring strain. Registration means researchers intend to study a question; it does not mean a treatment has been proven effective or safe. 8 9
What safety issues should patients ask a clinician about?
A clinician should review the injury itself, the product source, medical history, and alternatives before any injectable treatment is considered. There is no robust human safety dataset for BPC-157/TB-500 blends, so important risks and interactions may be unknown. 6
- Injection concerns: pain, redness, swelling, allergic reactions, contamination, and infection are possible with injected products. 1
- Liver safety: there is not enough reliable human evidence to call BPC-157 or TB-500 liver-safe or liver-toxic. A clinician should consider existing liver disease, symptoms, alcohol use, and other medicines. 6
- Medical history: pregnancy, breastfeeding, cancer history, immune conditions, clotting concerns, and prescription medicines can change the risk discussion. The evidence gaps are a reason for caution, not proof that use is harmless. 6
- Urgent symptoms: seek urgent care for trouble breathing, facial or throat swelling, fainting, rapidly spreading redness, fever, severe pain, chest pain, or signs of a serious allergic reaction or infection. 2
If you are weighing claims around adverse effects, our article on BPC-157 and TB-500 side effects separates known concerns from claims that lack adequate human data.
What are safer next steps if you are considering peptides for recovery?
Start with an accurate diagnosis and evidence-based injury care rather than a vial label. A licensed evaluation comes before any injection decision, especially for tendon injury, ligament injury, persistent joint pain, or a muscle strain that is not improving. 6
- 1Bring the full vial label, ingredient list, lot information, and source details to a licensed clinician. Do not assume that a “10 mg blend” label establishes what is inside.
- 2Avoid self-injecting products labeled “research use only.” Those products are not intended or labeled for human treatment. 1
- 3Ask what diagnosis is being treated, what established options exist, and what evidence supports each option. For muscle injuries, see our guide on speeding up muscle strain recovery safely.
- 4Treat dramatic forum claims as unproven unless they are backed by a well-designed human study. Preclinical mechanisms such as angiogenesis or cell migration are not the same as demonstrated recovery in people. 3 4
At Chia, we do not currently list BPC-157 or TB-500 in our live treatment catalog. We can help patients talk through broader health and recovery goals with a licensed provider, but a medical evaluation does not guarantee a prescription. Compounded medications, where prescribed for treatments we do offer, are prepared by state-licensed US 503A pharmacies and are not FDA-approved.
Frequently asked questions about BPC-157/TB-500 reconstitution
Robust human safety data are lacking, so it is not accurate to call BPC-157 either liver-safe or liver-toxic. Anyone with liver disease, concerning symptoms, or medication-related liver risks should discuss them with a licensed clinician. 6
No. Chia does not currently list BPC-157 or TB-500 in its live treatment catalog. Our providers can discuss your broader health goals and help you understand when an in-person injury evaluation or other evidence-based care may be needed.
References
- 1.U.S. Food and Drug Administration. Human Drug Compounding. FDA, 2026.
- 2.U.S. Food and Drug Administration. Buying and Using Medicine Safely. FDA, 2026.
- 3.Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research. 2019.
- 4.Seiwerth S, Rucman R, Turkovic B, et al. BPC 157 and Standard Angiogenic Growth Factors: Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing. Current Pharmaceutical Design. 2018.
- 5.Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021.
- 6.Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. The American Journal of Sports Medicine. 2026.
- 7.Choudry FA, Yeo C, Mozid A, et al. Increases in plasma Tβ4 after intracardiac cell therapy in chronic ischemic heart failure is associated with symptomatic improvement. Regenerative Medicine. 2015.
- 8.ClinicalTrials.gov. Impact of BPC-157 on Recovery Following Rotator Cuff Repair Surgery: NCT07803250. U.S. National Library of Medicine, 2026.
- 9.ClinicalTrials.gov. BPC 157 for Acute Hamstring Muscle Strain Repair: NCT07437547. U.S. National Library of Medicine, 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
